OBJECTIVE: To compare the results and side effects in treating uterine leiomyoma withgonadotrophin releasing hormone agonist (GnRH-a) or mifepristone. METHODS:75 patients with uterine leiomyoma who had clinical symptoms and diagnosed by Bcan were divided into two groups. The GnRH-a group (30 patients) was treated by injection of GnRH-a 150 micrograms/day subcutaneously for three months, and the mifepristone group (45 patients) was treated by mifepristone 12.5 mg/day po for three months. RESULTS: The clinical symptoms improved obviously in both groups. The volume of leiomyoma reduced 20.0% or more in 90.0% (27/30) of the patients in GnRH-a group, while it was 91.1% (41/45) in mifepristone group. However, the recurrent rates were 40.0% and 17.8% in the 2 groups. CONCLUSION: It suggested that mifepristone is a more practical and hopeful drug in treating uterine leiomyoma.
RCT Entities:
OBJECTIVE: To compare the results and side effects in treating uterine leiomyoma with gonadotrophin releasing hormone agonist (GnRH-a) or mifepristone. METHODS: 75 patients with uterine leiomyoma who had clinical symptoms and diagnosed by Bcan were divided into two groups. The GnRH-a group (30 patients) was treated by injection of GnRH-a 150 micrograms/day subcutaneously for three months, and the mifepristone group (45 patients) was treated by mifepristone 12.5 mg/day po for three months. RESULTS: The clinical symptoms improved obviously in both groups. The volume of leiomyoma reduced 20.0% or more in 90.0% (27/30) of the patients in GnRH-a group, while it was 91.1% (41/45) in mifepristone group. However, the recurrent rates were 40.0% and 17.8% in the 2 groups. CONCLUSION: It suggested that mifepristone is a more practical and hopeful drug in treating uterine leiomyoma.
Authors: Josep Ll Carbonell; Rita Acosta; Yasmiriam Pérez; Ana G Marrero; Edilia Trellez; Carlos Sánchez; Giuseppe Tomasi Journal: Int J Womens Health Date: 2013-03-19
Authors: Josep L Carbonell Esteve; Ana M Riverón; Mariela Cano; Alma I Ortiz; Aleta Valle; Carlos S Texidó; Giuseppe Tomasi Journal: Int J Womens Health Date: 2012-03-13